DR. ELIZABETH O'DAY
CEO & FOUNDER
Dr. Elizabeth O'Day is the CEO and Founder of Olaris, Inc., a precision medicine company that uses a pioneering metabolomics platform and proprietary machine learning algorithms to fundamentally improve how disease is diagnosed and treated. Olaris identifies “biomarkers of response” (BoR) to stratify patients into optimal treatment groups, increasing survival rates, decreasing adverse events and reducing unnecessary healthcare costs.
Outside of Olaris, Dr. O’Day plays an incredibly active role in partnering with government leaders and global organizations in advancing the field of precision medicine around the world. After founding Olaris, Dr. O’Day was invited to attend the first United State of Women Summit convened by the White House in 2016, and was recognized as a “nominated Change Maker.” She was also invited to participate in Vice President Joe Biden's Cancer Moonshot Summit to discuss collaborative ways “to end cancer as we know it.” In 2016, Dr. O’Day began serving as the co-chair of the World Economic Forum’s Global Future Council on Biotechnology. Over the last few years in this role, she has focused on leading the council in identifying policy opportunities capable of accelerating new biotech discoveries, and also guiding the dialogue about the implications of biotech advancements globally.
Most recently, Dr. O’Day was elected to serve a three-year term on the Personalized Medicine Coalition (PMC) Board of Directors beginning in June 2020. The PMC represents innovators, scientists, patients, providers and payers, to promote the understanding and adoption of personalized medicine concepts, services, and products to benefit patients and the health system. In this role, Dr. O’Day will collaborate with stakeholders across academia, industry, and government to increase access to personalized medicine.
Dr. O’Day is also supporting the next generation of scientists as adjunct faculty at Boston College, where she taught metabolism and entrepreneurship. Dr. O’Day was recognized by Boston Business Journal's as a 40 under 40 honoree in 2020. She is also on the Steering Committee and a contributor for Scientific American's annual "Top 10 Emerging Technologies".
During her graduate and undergraduate studies, Dr. O’Day received many of the most prestigious research awards for her personal scientific accomplishments. She earned her PhD from Harvard University, where she was a National Science Fellow; an MPhil in Chemistry from the University of Cambridge where she was a Churchill Fellow; and a BS in Biochemistry from Boston College where she was a Finnegan Award winner, Beckman Scholar, and Goldwater Scholar.